New, small-scale research from Xangle takes a look at investors’ reflections on their initial coin offering investments between 2017 and fall 2020.
You might also be interested in reading Exagen outlines $65M–$70M 2025 revenue target and positive adjusted EBITDA trajectory while advancing biomarker pipeline.
